J. Scott Daniels, PhD, Joins BASi as Senior Vice President of DMPK, Filling Key Scientific Leadership Position
March 07 2019 - 8:33AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the
“Company”) is pleased to announce the addition of J. Scott Daniels,
PhD, as Senior Vice President of DMPK, effective as of March 1,
2019. Dr. Daniels fills a strategic scientific leadership position
within the Company that in recent months has made other key
appointments to its organizational leadership following its
acquisition of Seventh Wave Laboratories in July of last year.
Dr. Daniels is an accomplished executive in pharmaceutical
research and development, and brings over fifteen years of
experience and leadership to the Company. He has advanced the
fields of biotransformation and drug metabolism during tenures at
DuPont Pharmaceuticals, Millennium, Pfizer, and Precera
Biosciences, publishing in areas of drug metabolism, chemical
toxicology and pharmacology.
“I have immense respect for Scott’s scientific expertise in the
fields of drug metabolism and pharmacokinetics, and bioanalytical
chemistry, and the utmost confidence in his ability to strengthen
our Company’s core leadership as we continue to assemble our
world-class scientific team,” said John E. Sagartz, DVM, PhD,
DACVP, BASi’s Chief Strategy Officer. “His appointment positions us
even more solidly towards providing premier support for our
clients’ R&D objectives and accelerating our growth as a
Company.”
Prior to joining BASi, Dr. Daniels was Chief Scientific Officer
at Precera Biosciences, and Director of Drug Metabolism and
Pharmacokinetics (DMPK) in the Center for Neuroscience Drug
Discovery at Vanderbilt University Medical
School. Dr. Daniels is an Adjunct Professor of Pharmacology at
Vanderbilt University School of Medicine. Dr. Daniels received his
undergraduate degree in Biology and Chemistry from Southwest
Baptist University and his doctorate in Chemistry at University of
Missouri-Columbia, and performed his post-doctoral research in
chemical toxicology at Vanderbilt University Medical Center.
“I couldn’t be more excited to be a part of this team and to
join a Company whose rich history and people I’ve known and admired
during a career in drug discovery and development,” said Dr.
Daniels. “When I think about the Company’s forward momentum and
broad spectrum of scientific expertise, I know that our integrated
drug metabolism and pharmacokinetic division will strengthen the
Company’s capabilities for supporting drug safety and pharmacology
studies and helping our clients reach their goals.”
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development
companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients’ discovery
and development objectives for improved decision-making and
accelerated goal attainment. BASi’s products focus on increasing
efficiency, improving data, and reducing the cost of taking new
drugs to market. Visit www.BASinc.com for more
information about BASi.
This release may contain forward-looking statements that are
subject to risks and uncertainties including, but not limited to,
risks and uncertainties related to changes in the market and demand
for our products and services, the development, marketing and sales
of products and services, changes in technology, industry and
regulatory standards, and various market and operating risks
detailed in the company's filings with the U.S. Securities and
Exchange Commission.
Company Contact:Jill C. BlumhoffChief Financial
OfficerPhone: 765.497.8381jblumhoff@BASinc.com
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024